Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies.
Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies.
复制标题
DOI：
10.1007/s00259-021-05439-4
复制
发表时间：
2022-03
影响因子：
9.1
通讯作者：
Taylor A
中科院分区：
文献类型：
--
作者：
Amadeo F;Plagge A;Chacko A;Wilm B;Hanson V;Liptrott N;Murray P;Taylor A
一种名为AkaBLI的新型红移生物发光成像（BLI）系统最近被开发用于临床前模型中的细胞跟踪，迄今为止，关于它与现有系统的表现的数据有限。系统地比较AkaBLI和标准萤火虫荧光素酶（FLuc）系统的性能，以监测啮齿动物细胞治疗的生物分布和命运。脐带间充质间质细胞（MSCs）被转导产生两个基因工程群体，分别表达AkaLuc或工程FLuc luc2。AkaLuc+和FLuc+细胞的生物发光在体外（发射光谱、饱和动力学和每个细胞的光发射）和体内（腹腔和皮下给药后的底物动力学和细胞的生物分布直到第7天）进行了评估。报告基因的引入对MSC表型无影响。对于BLI， FLuc系统在(i)光输出方面优于AkaBLI，在皮下底物递送后产生更强的信号，在腹腔内递送时产生更一致的信号动力学；（ii）没有肝脏背景；（iii）安全性，其中AkaLuc底物与小鼠体内皮肤中的反应有关。我们的结论是，使用AkaBLI系统来跟踪体内系统给药的基于细胞的再生医学疗法的生物分布没有优势。在线版本包含补充材料，可在10.1007/s00259-021-05439-4获得。
A novel, red-shifted bioluminescence imaging (BLI) system called AkaBLI has been recently developed for cell tracking in preclinical models and to date, limited data is available on how it performs in relation to existing systems. To systematically compare the performance of AkaBLI and the standard Firefly luciferase (FLuc) systems to monitor the biodistribution and fate of cell therapies in rodents. Umbilical cord mesenchymal stromal cells (MSCs) were transduced to produce two genetically engineered populations, expressing either AkaLuc or the engineered FLuc luc2. The bioluminescence of AkaLuc+ and FLuc+ cells was assessed both in vitro (emission spectra, saturation kinetics and light emission per cell) and in vivo (substrate kinetics following intraperitoneal and subcutaneous administration and biodistribution of the cells up to day 7). Introduction of the reporter genes has no effect on MSC phenotype. For BLI, the FLuc system is superior to AkaBLI in terms of (i) light output, producing a stronger signal after subcutaneous substrate delivery and more consistent signal kinetics when delivered intraperitoneally; (ii) absence of hepatic background; and (iii) safety, where the AkaLuc substrate was associated with a reaction in the skin of the mice in vivo. We conclude that there is no advantage in using the AkaBLI system to track the biodistribution of systemically administered cell-based regenerative medicine therapies in vivo. The online version contains supplementary material available at 10.1007/s00259-021-05439-4.
登录
查看更多内容
影响因子：
15
作者：
Reddy, Gadarla Randheer;Thompson, Walter C.;Miller, Stephen C.
通讯作者：
Miller, Stephen C.
影响因子：
3.5
作者：
Liang, Yajie;Walczak, Piotr;Bulte, Jeff W. M.
通讯作者：
Bulte, Jeff W. M.
DOI：
10.1007/s00259-008-1022-8
发表时间：
2009-05-01
影响因子：
9.1
作者：
Inoue, Yusuke;Kiryu, Shigeru;Ohtomo, Kuni
通讯作者：
Ohtomo, Kuni
影响因子：
2.9
作者：
Yeh, Hsien-Wei;Wu, Tianchen;Ai, Hui-wang
通讯作者：
Ai, Hui-wang
影响因子：
48
作者：
Evans, Melanie S.;Chaurette, Joanna P.;Adams, Spencer T., Jr.;Reddy, Gadarla R.;Paley, Miranda A.;Aronin, Neil;Prescher, Jennifer A.;Miller, Stephen C.
通讯作者：
Miller, Stephen C.